HC Wainwright Reiterates Buy Rating for BioLineRx (NASDAQ:BLRX)

HC Wainwright reaffirmed their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a research report released on Wednesday,Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q3 2024 earnings at ($0.03) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.10) EPS.

Separately, StockNews.com initiated coverage on BioLineRx in a research note on Thursday, October 31st. They issued a “hold” rating on the stock.

BioLineRx Stock Performance

BioLineRx stock opened at $0.44 on Wednesday. The company has a market cap of $35.54 million, a PE ratio of -0.99 and a beta of 1.48. The company has a fifty day moving average price of $0.53 and a two-hundred day moving average price of $0.63. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. BioLineRx has a 12 month low of $0.39 and a 12 month high of $1.93.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. Research analysts expect that BioLineRx will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On BioLineRx

Hedge funds have recently added to or reduced their stakes in the stock. PVG Asset Management Corp bought a new stake in BioLineRx in the second quarter valued at $70,000. CVI Holdings LLC bought a new stake in shares of BioLineRx during the second quarter valued at about $462,000. Finally, Atria Investments Inc raised its stake in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares in the last quarter. 1.56% of the stock is currently owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.